Economic Burden of Parkinson's Disease: A Multinational, Real-World, Cost-of-Illness Study.
Kallol Ray ChaudhuriJean-Philippe AzulayPer OdinSusanna LindvallJosefa M M DomingosAli AlobaidiPrasanna L KandukuriVivek S ChaudhariJuan Carlos ParraToru YamazakiJulia OddsdottirJack WrightPablo Martínez-MartínPublished in: Drugs - real world outcomes (2024)
People with Parkinson's disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson's disease and their caregivers, whilst also substantially impacting societal costs.